Streetbeat News

Products Services

ALNY

The FDA advisory committee has voted in favor of a new indication for Alnylam's drug, Onpattro. This positive development could potentially expand the drug's market and boost Alnylam's revenues.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:36 pm

SCNI

Scinai Immunotherapeutics announced positive results in a preclinical study of its anti‑interleukin 17 NanoAbs treatment for plaque psoriasis, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:35 pm

AYRO

AYRO has entered low-rate initial production of the Vanish, a low-speed electric vehicle (EV). The first units are expected to be delivered to initial channel partners within weeks.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:32 pm

MRNA

Moderna has announced that the late-stage study results for its Cytomegalovirus vaccine candidate may be available as early as the end of next year.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:26 pm

TPIC

TPI Composites, in collaboration with the University of Tennessee Knoxville, is advancing the creation of glass fiber yarns from recycled wind turbine blades. This initiative is part of TPI's commitment to sustainability and circular economy.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:26 pm

SCNI

Scinai Immunotherapeutics has reported preclinical results for its innovative plaque psoriasis treatment, NanoAbs. The treatment has shown to downregulate key molecular markers overexpressed in plaque psoriasis and helped the stratum corneum regain a normal appearance in a laboratory 3D skin model. Results from an ex-vivo study in human psoriatic skin are expected in Q4 2023, and in-vivo animal study results are anticipated in early 2024.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:24 pm

SCNI

Scinai Immunotherapeutics has announced results from a preclinical study of IL-17 NanoAbs, which showed downregulated key molecular markers overexpressed in plaque psoriasis.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:21 pm

ON

Piper Sandler analyst Harsh V. Kumar reaffirmed an Overweight rating on ON Semiconductor Corp (NASDAQ:ON) with a price target of $135. Despite macroeconomic challenges, Kumar believes ON is on track to perform well due to its strong position in Silicon Carbide (SiC) and growth in other automotive products. ON has $20 billion in long-term supply agreements, $11 billion of which are related to SiC products. The company is on track to exit this year with roughly $1 billion of SiC revenues and expects the SiC business operating income to exceed corporate operating income by the end of 2025.

Portfolio Pulse from Anusuya Lahiri

September 13, 2023 | 8:15 pm

CHTR

DIS

NFLX

Charter Communications' CFO, Jessica Fischer, has hailed the recent contract renewal with Walt Disney Co as a victory for pay-TV providers. The agreement includes Charter offering Disney+ and ESPN+ streaming services to its subscribers at no extra cost. Charter will pay Disney a wholesale rate for Disney+ and receive ESPN+ as part of the deal. Charter will discontinue specific Disney channels, including Freeform and Disney Junior. Disney secures higher fees for its channels, such as ABC and FX, and Charter commits to providing ESPN to a minimum of 85% of its customers.

Portfolio Pulse from Anusuya Lahiri

September 13, 2023 | 8:11 pm

ABBV

HARP

Harpoon Therapeutics announced that AbbVie will not exercise the exclusive license option of the HPN217 program, as per their Development and Option Agreement. The agreement will terminate on October 12, 2023. Harpoon will retain exclusive ownership of the HPN217 program and plans to complete the ongoing Phase 1 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 8:09 pm